Microcap Ledger In8bio, Inc. $INAB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- New York, NY
- Fiscal year end
- December 31
- Shares outstanding
- 9,858,383 [10-Q 2026-08-06]
What the company doesAI summary of filing
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers for cancer and autoimmune diseases. The company's DeltEx platform uses ex vivo expanded and genetically modified gamma-delta T cells, employing allogeneic, autologous, and iPSC-derived approaches. IN8bio has two clinical programs with demonstrated durable remissions: INB-100 (allogeneic gamma-delta T cells for leukemia patients undergoing stem cell transplantation) and INB-200/INB-400 (genetically modified gamma-delta T cells for glioblastoma). The company is pre-revenue and has stated that its existing cash of $27.1 million as of December 31, 2025, is not anticipated to fund operations beyond April 2027, raising substantial doubt about its ability to continue as a going concern. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$9.87M | −$8.69M | $18.13M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | −$19.44M | −$12.71M | $27.31M | [10-K 2026-03-12] |
| FY ended Dec 2024 | — | −$30.44M | −$24.15M | $11.39M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$4.35M
- Cash runway Estimate
- ~12.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-05-06 | 44,123,949 | [10-Q 2024-05-09] |
| 2024-08-07 | 46,786,948 | [10-Q 2024-08-08] |
| 2024-11-11 | 72,483,253 | [10-Q 2024-11-12] |
| 2025-05-02 | 90,771,944 | [10-K/A 2025-05-07] |
| 2025-08-03 | 4,539,717 | [10-Q 2025-08-07] |
| 2025-11-03 | 4,634,396 | [10-Q 2025-11-06] |
| 2026-05-04 | 9,847,089 | [10-Q 2026-05-07] |
| 2026-08-03 | 9,858,383 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-01-20; declared effective 2026-01-28 [S-3 2026-01-20]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-02-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-02-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-07] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-27 | Fairbairn Emily | other | 724,637 | — | [4 2026-05-29] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-01 | 8-K | Material agreement entered; Material agreement terminated |
| 2026-06-01 | 424B5 | Prospectus or prospectus supplement |
| 2026-05-29 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-18 | S-3/A | Registration statement |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations; Director or officer change; Shareholder vote results |
| 2026-03-26 | DEF 14A | Proxy statement |
| 2026-03-12 | 10-K | Annual report |
| 2026-03-12 | 8-K | Results of operations |
Alerts for $INAB
Email me when In8bio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.